Day One Biopharmaceuticals (NASDAQ:DAWN) Releases Earnings Results, Beats Estimates By $0.58 EPS

Day One Biopharmaceuticals (NASDAQ:DAWN) posted its earnings results on Wednesday. The company reported $0.38 EPS for the quarter, beating the consensus estimate of ($0.20) by $0.58, Briefing.com reports. The business had revenue of $93.76 million during the quarter, compared to analysts’ expectations of $15.05 million. During the same period last year, the company earned ($0.54) EPS.

Day One Biopharmaceuticals Price Performance

Shares of NASDAQ:DAWN opened at $14.65 on Friday. Day One Biopharmaceuticals has a 1-year low of $10.90 and a 1-year high of $18.07. The stock has a market cap of $1.29 billion, a P/E ratio of -14.22 and a beta of -1.51. The firm has a fifty day moving average price of $14.19 and a 200 day moving average price of $14.39.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on DAWN. Wedbush reiterated an “outperform” rating and issued a $33.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday, July 25th. Bank of America raised shares of Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and raised their price objective for the stock from $11.00 to $24.00 in a report on Thursday, August 1st. HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of Day One Biopharmaceuticals in a research report on Thursday. Piper Sandler reaffirmed an “overweight” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Monday, July 8th. Finally, JPMorgan Chase & Co. reduced their price target on shares of Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, Day One Biopharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $35.71.

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 2,232 shares of the company’s stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $14.00, for a total transaction of $31,248.00. Following the completion of the sale, the insider now directly owns 1,127,535 shares of the company’s stock, valued at $15,785,490. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, insider Samuel C. Blackman sold 30,000 shares of the business’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $14.22, for a total transaction of $426,600.00. Following the transaction, the insider now directly owns 1,097,535 shares in the company, valued at $15,606,947.70. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Samuel C. Blackman sold 2,232 shares of the stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $14.00, for a total transaction of $31,248.00. Following the transaction, the insider now directly owns 1,127,535 shares of the company’s stock, valued at $15,785,490. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 48,748 shares of company stock worth $689,072. 8.40% of the stock is owned by company insiders.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.